EP
GLUE icon

Essential Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Essential Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9K Sell
821
-12,207
-94% -$231K 0.01% 909
2026
Q1 		$214K Sell
13,028
-100
-0.8% -$1.91K 0.07% 278
2025
Q4 		$206K Buy
13,128
+106
+0.8% +$1.43K 0.06% 309
2025
Q3 		$96.5K Buy
13,022
+20
+0.2% +$106 0.03% 439
2025
Q2 		$58.6K Buy
+13,002
New +$58K 0.02% 439

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Essential Partners's GLUE Position: Q2 2026 in Review

Essential Partners reduced its Monte Rosa Therapeutics (GLUE) stake by 94% in Q2 2026, selling an estimated $231K and leaving 821 shares worth $19.9K. The position accounts for 0.01% of the portfolio, ranked #909.

Essential Partners first reported a position in GLUE in Q2 2025 and has held it in 5 quarters since. The position peaked at $214K in Q1 2026. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Essential Partners held 821 shares of Monte Rosa Therapeutics worth $19.9K as of Q2 2026.
  • Essential Partners sold 12,207 Monte Rosa Therapeutics shares in Q2 2026, an estimated $231K.
  • Monte Rosa Therapeutics made up 0.01% of Essential Partners's portfolio in Q2 2026, its #909 holding.
  • Essential Partners first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Monte Rosa Therapeutics position peaked at $214K in Q1 2026.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.